**Background of Ras Antibodies**
Ras proteins are small GTPases that act as molecular switches, regulating key cellular processes like proliferation, differentiation, and survival. Mutations in *RAS* genes (KRAS, NRAS, HRAS) are among the most common drivers of human cancers, occurring in ~20% of malignancies, particularly pancreatic, colorectal, and lung cancers. These mutations, often at residues G12. G13. or Q61. lock Ras in a hyperactive GTP-bound state, leading to uncontrolled signaling through pathways like MAPK/ERK and PI3K/AKT. Historically, Ras was deemed “undruggable” due to its smooth surface, lack of deep binding pockets, and high affinity for GTP/GDP, complicating small-molecule inhibitor development.
Antibodies targeting Ras have emerged as alternative therapeutic strategies. Early efforts focused on blocking Ras-membrane association or effector interactions but faced challenges due to Ras’s intracellular localization and structural constraints. Advances in antibody engineering, including intracellular delivery systems (e.g., nanobodies, mRNA-based delivery) and mutation-specific targeting, have revitalized this field. For example, antibodies against KRAS G12C or G12D mutants selectively inhibit oncogenic Ras signaling while sparing wild-type proteins. Additionally, some antibodies promote Ras degradation via ubiquitination or disrupt Ras-nanocluster formation.
Despite progress, challenges remain, such as tumor heterogeneity, resistance mechanisms, and delivery efficiency. Current research focuses on optimizing antibody affinity, specificity, and compatibility with combination therapies (e.g., immune checkpoint inhibitors). Ras antibodies represent a promising avenue to address a critical unmet need in oncology, bridging the gap between basic research and clinical translation.